|Dr. Laurence James Neil Cooper||CEO & Director||1.59M||N/A||1965|
|Dr. David M. Mauney M.D.||Pres||608.76k||N/A||1969|
|Mr. Robert Hadfield||Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer||376.7k||N/A||1978|
|Mr. Satyavrat Shukla||Exec. VP & CFO||N/A||N/A||1972|
|Ms. Lynn M. Ferrucci||Exec. VP of HR, Facilities, Admin. & IT||N/A||N/A||N/A|
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 4. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 2; Compensation: 7.